PMID- 26732314
OWN - NLM
STAT- MEDLINE
DCOM- 20161006
LR  - 20181113
IS  - 1478-6362 (Electronic)
IS  - 1478-6354 (Print)
IS  - 1478-6354 (Linking)
VI  - 18
DP  - 2016 Jan 6
TI  - Progress in defining clinically meaningful changes for clinical trials in 
      nonrenal manifestations of SLE disease activity.
PG  - 1
LID - 10.1186/s13075-015-0906-9 [doi]
LID - 1
AB  - Since the 2002 Dusseldorf meeting, one new agent, Benlysta, has been approved by 
      the US Food and Drug Administration for systemic lupus erythematosus. Experiences 
      from the field in conducting trials of all the agents tested during this period 
      have provided valuable practical insights. There has been incremental progress in 
      defining the minimal clinically important difference (MCID) of key disease 
      manifestations and the view is largely that of the health care providers and not 
      that of the person suffering the disease. This basic methodological work on the 
      MCID should improve the efficiency and the clinical relevance of future trials 
      and their design.
FAU - Choi, Chan-Bum
AU  - Choi CB
AD  - Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, 
      222-1 Wangsimni-ro, Seongdong-gu, Seoul, 04763, Republic of Korea.
AD  - Department of Aging, Brigham and Women's Hospital, Section of Rheumatology, 75 
      Francis St., Boston, MA, 02115, USA.
AD  - VA Healthcare System, 150 S Huntington Ave, Jamaica Plain, MA, 02130, USA.
FAU - Liang, Matthew H
AU  - Liang MH
AD  - Department of Aging, Brigham and Women's Hospital, Section of Rheumatology, 75 
      Francis St., Boston, MA, 02115, USA. mhliang@partners.org.
AD  - Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, 
      75 Francis Street, Boston, MA, 02115, USA. mhliang@partners.org.
FAU - Bae, Sang-Cheol
AU  - Bae SC
AD  - Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, 
      222-1 Wangsimni-ro, Seongdong-gu, Seoul, 04763, Republic of Korea.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20160106
PL  - England
TA  - Arthritis Res Ther
JT  - Arthritis research & therapy
JID - 101154438
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 73B0K5S26A (belimumab)
SB  - IM
MH  - Antibodies, Monoclonal, Humanized/therapeutic use
MH  - Clinical Trials as Topic/*methods
MH  - Cognition Disorders/diagnosis/drug therapy/epidemiology
MH  - *Disease Progression
MH  - Fatigue/diagnosis/drug therapy/epidemiology
MH  - Humans
MH  - Lupus Erythematosus, Systemic/*diagnosis/drug therapy/*epidemiology
MH  - Skin Diseases/diagnosis/drug therapy/epidemiology
PMC - PMC4718037
EDAT- 2016/01/07 06:00
MHDA- 2016/10/08 06:00
PMCR- 2016/01/06
CRDT- 2016/01/07 06:00
PHST- 2016/01/07 06:00 [entrez]
PHST- 2016/01/07 06:00 [pubmed]
PHST- 2016/10/08 06:00 [medline]
PHST- 2016/01/06 00:00 [pmc-release]
AID - 10.1186/s13075-015-0906-9 [pii]
AID - 906 [pii]
AID - 10.1186/s13075-015-0906-9 [doi]
PST - epublish
SO  - Arthritis Res Ther. 2016 Jan 6;18:1. doi: 10.1186/s13075-015-0906-9.